Pharmaceutical Care Program for Type 2 Diabetes Mellitus

NCT ID: NCT02435693

Last Updated: 2015-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

1. To evaluate Pharmaceutical care program in Type2 diabetics.
2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
3. To study the prevalence of Type2 diabetics cases in Dhule.
4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DIABETES MELLITUS, TYPE 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PHARMACEUTICAL CARE programe

The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Group Type EXPERIMENTAL

PHARMACEUTICAL CARE programe

Intervention Type OTHER

The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

control

without pharmaceutical care programe (control)

Group Type OTHER

Without PHARMACEUTICAL CARE programe

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PHARMACEUTICAL CARE programe

The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Intervention Type OTHER

Without PHARMACEUTICAL CARE programe

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with type 2 diabetes mellitus of either
* Patients with HbA1c more than 7% and
* Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria

* Patient with end stage kidney disease.
* Patient with heart failure.
* Patient with chronic Diabetes problem and orthopedic problem
Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TABREJ MUJAWAR

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

TABREJ MUJAWAR

tabrej mujawar mpharm Study principal investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

tabrej aj mujawar, mpharm

Role: PRINCIPAL_INVESTIGATOR

muhs

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tabrej Aj Mujawar

Dhule, Maharashtra, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

pc

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Patients With Type 2 Diabetes
NCT07245082 RECRUITING
Indian Phenotype Registry
NCT03363594 COMPLETED
Menses&Change in Diabetic Girl
NCT07194291 NOT_YET_RECRUITING